- Home
- TOUR vs NTHI Comparison
TOUR vs NTHI Comparison
Compare TOUR & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOUR
- NTHI
- Stock Information
- Founded
- TOUR 2006
- NTHI 2008
- Country
- TOUR China
- NTHI United States
- Employees
- TOUR N/A
- NTHI N/A
- Industry
- TOUR Transportation Services
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- TOUR Consumer Discretionary
- NTHI Health Care
- Exchange
- TOUR Nasdaq
- NTHI Nasdaq
- Market Cap
- TOUR 101.0M
- NTHI 142.5M
- IPO Year
- TOUR 2014
- NTHI N/A
- Fundamental
- Price
- TOUR $0.91
- NTHI $7.24
- Analyst Decision
- TOUR
- NTHI
- Analyst Count
- TOUR 0
- NTHI 0
- Target Price
- TOUR N/A
- NTHI N/A
- AVG Volume (30 Days)
- TOUR 122.4K
- NTHI 108.1K
- Earning Date
- TOUR 06-12-2025
- NTHI 01-01-0001
- Dividend Yield
- TOUR 3.96%
- NTHI N/A
- EPS Growth
- TOUR N/A
- NTHI N/A
- EPS
- TOUR 0.09
- NTHI N/A
- Revenue
- TOUR $70,367,853.00
- NTHI $79,990.00
- Revenue This Year
- TOUR $16.99
- NTHI N/A
- Revenue Next Year
- TOUR $13.23
- NTHI N/A
- P/E Ratio
- TOUR $10.54
- NTHI N/A
- Revenue Growth
- TOUR 16.40
- NTHI 13.52
- 52 Week Low
- TOUR $0.71
- NTHI $4.11
- 52 Week High
- TOUR $1.76
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- TOUR 46.11
- NTHI N/A
- Support Level
- TOUR $0.88
- NTHI N/A
- Resistance Level
- TOUR $0.94
- NTHI N/A
- Average True Range (ATR)
- TOUR 0.03
- NTHI 0.00
- MACD
- TOUR -0.00
- NTHI 0.00
- Stochastic Oscillator
- TOUR 25.44
- NTHI 0.00
About TOUR Tuniu Corporation
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").